Gabapentin
Product Images NDC 69176-200

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 69176-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tmig Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gaba90 (Gaba300 90final)

Gabapentin Capsules USP 300 mg label showing 90 capsules in the package. Distributed by TMIG Inc., it includes storage instructions at room temperature (68-77°F), a notice to keep out of reach of children, and manufacturing details by Alkem Laboratories Limited, Mumbai, India. The label also features an NDC code 69176-200-90 and barcode.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula for calculating creatinine clearance (CLCr) based on patient age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients. The formula is shown as a mathematical expression involving these variables.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

Line graph depicting mean pain score over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to 8 weeks, and the y-axis shows mean pain score from 0 to 10. Periods include a 4-week dose titration followed by a 4-week fixed dose. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph illustrating mean pain scores over 7 weeks comparing placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents time in weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores decreasing over time for both Gabapentin doses, with placebo scores remaining higher.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data for two studies. Study 1 compares placebo (12%) and Gabapentin 3600 mg (29%). Study 2 compares placebo (14%), Gabapentin 1800 mg (32%), and Gabapentin 2400 mg (34%). Statistical significance is indicated with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot showing the percentage difference versus daily dose in mg for Gabapentin across three studies labeled a, b, and c. The horizontal axis represents daily doses from 600 to 1800 mg, while the vertical axis shows differences from 2% to 22%. Different study results are marked by distinct symbols and colors.*

FDA Label Image

Gabapentin Structure (Gabapentin Struc)

Chemical structure diagram of gabapentin. The structure shows a cyclohexane ring attached to an amino group (CH2NH2) and a carboxyl group (CH2CO2H), depicting the molecular framework of gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.